Study | Drug dose | No. subjects | Mean CD4 Count a (cells/μl) | % On ART | Median Follow-up time b (days) | Primary MAC events (N) | Direct monthly failure rate (95% CI) | Direct monthly probability of failure |
---|---|---|---|---|---|---|---|---|
Nightingale 1993, study 023 and 027c[13] | Rifabutin, 300 mg, qd | 283 | 64 | 100 | 209 d | 24 | 0.012 (0.007-0.017) | 0.012 |
 | Placebo | 290 | 56 | 100 | 202 d | 51 | 0.027 (0.019-0.0034) | 0.026 |
Havlir 1996[17] | Rifabutin, 300 mg, qd | 223 | 47 | -- | 514 | 52 | 0.014 (0.010-0.018) | 0.014 |
 | Azithromycin, 1200 mg, qwk | 223 | 49 | -- | 514 | 31 | 0.008 (0.005-0.011) | 0.008 |
Benson 2000[16] | Rifabutin, 300 e mg, qd | 391 | 30 | 75 | 574 | 59 | 0.008 (0.006-0.010) | 0.008 |
 | Clarithromycin, 500 mg, bid | 398 | 27 | 73 | 595 | 36 | 0.005 (0.003-0.006) | 0.005 |
Pierce 1996[14] | Clarithromycin, 500 mg, bid | 333 | 30 | -- | 427 f | 19 | 0.004 (0.002-0.006) | 0.004 |
 | Placebo | 334 | 25 | -- | 402 f | 53 | 0.012 (0.009-0.015) | 0.012 |
Oldfield 1998[15] | Azithromycin, 1200 mg, qwk | 85 | 44 | -- | 400 d | 9 g | 0.008 (0.003-0.013) | 0.008 |
 | Placebo | 89 | 44 | -- | 340 d | 24 g | 0.024 (0.015-0.034) | 0.024 |